Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Total Liabilities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Total Liabilities for 8 consecutive years, with $43.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities changed N/A to $43.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $43.9 million for FY2025, N/A changed from the prior year.
  • Total Liabilities for Q4 2025 was $43.9 million at Actinium Pharmaceuticals, up from $42.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $47.7 million in Q4 2022, with the low at $4.0 million in Q2 2021.
  • Average Total Liabilities over 5 years is $34.3 million, with a median of $43.9 million recorded in 2025.
  • The sharpest move saw Total Liabilities skyrocketed 1002.88% in 2022, then decreased 5.54% in 2023.
  • Over 5 years, Total Liabilities stood at $6.8 million in 2021, then skyrocketed by 597.22% to $47.7 million in 2022, then fell by 5.54% to $45.1 million in 2023, then fell by 2.57% to $43.9 million in 2024, then increased by 0.08% to $43.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $43.9 million, $42.4 million, and $44.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.